MX1NA
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in MX1NA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in MX1NA
N/A
MX1NA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in MX1NA also invest in...
Want more shares? Try these...
MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is primarily focused on the development and supply of standardized phytomedicines to patients globally. The company has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy; CogniCann, in a Phase II trial for symptomatic relief of Dementia, and Irnican, a preclinical medicine to be used for treatment for Glioblastoma. The firm is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. The company has a product offering targeting two medical conditions, which include epilepsy and dementia. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.
📊 Share price
$0.01 AUD
Micro-X Ltd. manufactures, designs, and develops ultra-lightweight carbon nanotube based X-ray products for the global healthcare and explosive device markets. The company is headquartered in Adelaide, South Australia. The company went IPO on 2015-12-22. The firm is engaged in the design, development and manufacturing of ultra-lightweight carbon nanotube-based X-ray products for the global healthcare and security markets. Its lead-patented carbon nanotube technology ensures its products are lighter, smaller and more portable than traditional X-ray devices. The Company’s products include mobile digital X-ray machines, intermittent explosive disorder (IED) X-ray camera, miniature baggage scanner and computed tomography (CT) brain scanner. Its commercial mobile digital radiology products are sold for diagnostic imaging in global healthcare, military, and veterinary applications. The company is also advancing the development of X-ray Camera for security imaging of improvised explosive devices. The company is also focused on designing Airport Checkpoint Portal with self-service x-ray for the United States Department of Homeland Security.
📊 Share price